FibroBiologics CFO granted 61,607 stock options

FibroBiologics, Inc. reported that Chief Financial Officer Jason Davis received a grant of stock options covering 61,607 shares of common stock at an exercise price of $1.38 per share.

Rhea-AI Filing Summary

FibroBiologics, Inc. reported that Chief Financial Officer Jason Davis received a grant of stock options covering 61,607 shares of common stock at an exercise price of $1.38 per share. The options expire on May 4, 2036 and represent a compensation award, not an open-market trade.

According to the vesting terms, one quarter of the option shares will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments as long as Davis remains in continuous service. Following this grant, he holds 61,607 stock options directly.

Insider Trade Summary

Grant/Award: 61,607 shares

Grant/Award 1 txn

Insider Davis Jason

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	61,607	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 61,607 contracts (Direct)

Footnotes (1)

1. F1. On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.

Key Figures

Option grant size: 61,607 shares Exercise price: $1.38 per share Expiration date: May 4, 2036 +3 more

6 metrics

Option grant size 61,607 shares Stock options granted to CFO Jason Davis on May 4, 2026

Exercise price $1.38 per share Strike price for Jason Davis’s stock options

Expiration date May 4, 2036 Option term end for Jason Davis’s grant

Post-grant option holdings 61,607 options Total derivative securities held by Jason Davis after grant

Cliff vesting portion 25% of options Vests on first anniversary of grant date

Remaining vesting schedule 36 monthly installments Balance of options vesting after initial one-year cliff

Key Terms

Stock Option (Right to Buy), exercise price, vesting, continuous service, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.3800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"option shares shall vest on the one-year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"until fully vested so long as the reporting person remains in continuous service"

expiration date financial

"expiration_date: 2036-05-04T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FibroBiologics (FBLG) disclose about CFO Jason Davis in this Form 4?

FibroBiologics reported that CFO Jason Davis received a grant of 61,607 stock options. The award is a compensation-related option grant, not an open-market share purchase or sale, and gives him the right to buy common stock at a fixed exercise price.

How many FibroBiologics (FBLG) shares are covered by Jason Davis’s new stock options?

The new option grant to Jason Davis covers 61,607 shares of FibroBiologics common stock. These options give him the right to purchase that number of shares if they vest and he chooses to exercise them during the option term.

What is the exercise price and expiration date of Jason Davis’s FibroBiologics options?

Jason Davis’s stock options have an exercise price of $1.38 per share and expire on May 4, 2036. This means he can buy shares at $1.38, once vested, any time before the listed expiration date if he chooses to exercise.

How do Jason Davis’s FibroBiologics stock options vest over time?

One quarter of Jason Davis’s options vest on the first anniversary of the May 4, 2026 grant date. The remaining shares then vest in 36 equal monthly installments, contingent on his continued service with the company through each applicable vesting period.

Is Jason Davis’s Form 4 transaction in FibroBiologics stock a market buy or sell?

The Form 4 reflects a grant of stock options to Jason Davis, not a market buy or sell. The transaction is coded as an award, giving him future rights to purchase shares rather than reporting an immediate open-market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 07:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Jason

(Last) (First) (Middle)

C/O FIBROBIOLOGICS, INC.

9350 KIRBY DRIVE., SUITE 300

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.38	05/04/2026		A		61,607		(1)	05/04/2036	Common Stock	61,607	$0	61,607	D

Explanation of Responses:

1. On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.

	/s/ Ruben A. Garcia, by Power of Attorney	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)